CO6362048A2 - Moleculas de anticuerpo mejoradas - Google Patents
Moleculas de anticuerpo mejoradasInfo
- Publication number
- CO6362048A2 CO6362048A2 CO11045364A CO11045364A CO6362048A2 CO 6362048 A2 CO6362048 A2 CO 6362048A2 CO 11045364 A CO11045364 A CO 11045364A CO 11045364 A CO11045364 A CO 11045364A CO 6362048 A2 CO6362048 A2 CO 6362048A2
- Authority
- CO
- Colombia
- Prior art keywords
- tocilizumab
- present
- superior
- amino acid
- pharmaceutical compositions
- Prior art date
Links
- 229960003989 tocilizumab Drugs 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
La presente invención proporciona composiciones farmacéuticas que comprenden moléculas de segunda generación que son superior a TOCILIZUMAB, por alteración de las secuencias de aminoácidos de las regiones variable y constante de TOCILIZUMAB, que es un anticuerpo lgG1 anti-receptor de IL-6 humanizado, para mejorar la capacidad para neutralizar antígenos y para incrementar la farmacocinética, de modo tal que se ejerce un efecto terapéutico con una menor frecuencia de administración, y se logran mejoras de la inmunogenicidad, seguridad y propiedades fisicoquímicas (estabilidad y homogeneidad). La presente invención también proporciona métodos para producir estas composiciones farmacéuticas. Los inventores de la presente han generado con éxito moléculas de segunda generación que son superiores a TOCILIZUMAB mediante una combinación apropiada de estas alteraciones de la secuencia de aminoácidos en los dominios CDR, regiones variables y regiones constantes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008248213 | 2008-09-26 | ||
| JP2009060806 | 2009-03-13 | ||
| JP2009067925 | 2009-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6362048A2 true CO6362048A2 (es) | 2012-01-20 |
Family
ID=42059767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11045364A CO6362048A2 (es) | 2008-09-26 | 2011-04-12 | Moleculas de anticuerpo mejoradas |
Country Status (36)
| Country | Link |
|---|---|
| US (9) | US8562991B2 (es) |
| EP (1) | EP2330193B1 (es) |
| JP (2) | JP4550938B2 (es) |
| KR (2) | KR101044180B1 (es) |
| CN (2) | CN101849006B (es) |
| AR (2) | AR073404A1 (es) |
| AU (1) | AU2009290162B2 (es) |
| BR (1) | BRPI0905076B8 (es) |
| CA (2) | CA2699834C (es) |
| CL (1) | CL2011000632A1 (es) |
| CO (1) | CO6362048A2 (es) |
| CR (1) | CR20110204A (es) |
| DK (1) | DK2330193T3 (es) |
| EC (1) | ECSP11011003A (es) |
| ES (1) | ES2546800T3 (es) |
| FI (1) | FIC20210049I1 (es) |
| FR (1) | FR21C1054I2 (es) |
| HK (2) | HK1147107A1 (es) |
| HR (1) | HRP20150857T1 (es) |
| HU (2) | HUE027533T2 (es) |
| IL (1) | IL211850A0 (es) |
| LT (1) | LTC2330193I2 (es) |
| MA (1) | MA32707B1 (es) |
| MX (1) | MX2010003256A (es) |
| MY (1) | MY153908A (es) |
| NL (1) | NL301152I2 (es) |
| NO (1) | NO2021048I1 (es) |
| NZ (1) | NZ592214A (es) |
| PE (1) | PE20120079A1 (es) |
| PL (1) | PL2330193T3 (es) |
| PT (1) | PT2330193E (es) |
| RU (1) | RU2430111C3 (es) |
| SI (1) | SI2330193T1 (es) |
| TW (1) | TWI440469B (es) |
| WO (1) | WO2010035769A1 (es) |
| ZA (1) | ZA201103027B (es) |
Families Citing this family (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2284271C (en) | 1997-03-21 | 2012-05-08 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
| AR061400A1 (es) * | 2005-10-14 | 2008-08-27 | Chugai Kabushiki Kaisha | Agentes para suprimir el dano a los islotes transplantados despues del transplante de islotes |
| RU2450830C2 (ru) | 2005-10-21 | 2012-05-20 | Чугаи Сейяку Кабусики Кайся | Средства для лечения кардиопатии |
| AR057582A1 (es) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| CA2637917C (en) | 2006-01-27 | 2015-11-24 | Keio University | Therapeutic agents for diseases involving choroidal neovascularization |
| EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| CN101479381B (zh) * | 2006-03-31 | 2015-04-29 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| WO2007116962A1 (ja) | 2006-04-07 | 2007-10-18 | Osaka University | 筋再生促進剤 |
| KR101508019B1 (ko) | 2007-01-23 | 2015-04-06 | 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 | 만성 거부반응 억제제 |
| CN101874041B (zh) * | 2007-09-26 | 2013-06-19 | 中外制药株式会社 | 抗体恒定区修饰体 |
| EP2202245B1 (en) | 2007-09-26 | 2016-08-24 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| US20110129459A1 (en) | 2007-12-05 | 2011-06-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-nr10 antibody and use thereof |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| TW201447062A (zh) | 2008-04-11 | 2014-12-16 | Chugai Pharmaceutical Co Ltd | 重複結合複數個抗原的抗原結合分子 |
| CN104906581A (zh) | 2008-06-05 | 2015-09-16 | 国立研究开发法人国立癌症研究中心 | 神经浸润抑制剂 |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| TWI457134B (zh) * | 2009-03-19 | 2014-10-21 | Chugai Pharmaceutical Co Ltd | Rheumatoid arthritis treatment |
| EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| EP2409990A4 (en) | 2009-03-19 | 2013-01-23 | Chugai Pharmaceutical Co Ltd | VARIANT OF A CONSTANT ANTIBODY REGION |
| EP4406615A3 (en) | 2009-10-26 | 2024-12-11 | F. Hoffmann-La Roche AG | Method for the production of a glycosylated immunoglobulin |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| TWI667257B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| DK2578231T3 (da) | 2010-05-28 | 2022-12-12 | Chugai Pharmaceutical Co Ltd | Antitumor-t-celle-reaktionsforstærker |
| JP6173911B2 (ja) | 2010-09-10 | 2017-08-09 | メディミューン リミテド | 抗体誘導体 |
| JP2013541594A (ja) | 2010-11-08 | 2013-11-14 | ジェネンテック， インコーポレイテッド | 皮下投与される抗ｉｌ−６受容体抗体 |
| TR201802772T4 (tr) | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül. |
| KR102385507B1 (ko) | 2010-11-30 | 2022-04-12 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| US20140080153A1 (en) * | 2011-01-07 | 2014-03-20 | Chugai Seiyaku Kabushiki Kaisha | Method for improving physical properties of antibody |
| PT2668212T (pt) | 2011-01-28 | 2018-06-28 | Sanofi Biotechnology | Anticorpos humanos para pcsk9 para uso em métodos de tratar grupos específicos de sujeitos |
| US20140093496A1 (en) * | 2011-02-25 | 2014-04-03 | Chugai Seiyaku Kabushiki Kaisha | Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY |
| WO2012132067A1 (ja) * | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| AU2012223449A1 (en) | 2011-03-03 | 2013-05-02 | Apexigen, Inc. | Anti-IL-6 receptor antibodies and methods of use |
| JP5636331B2 (ja) * | 2011-04-28 | 2014-12-03 | シスメックス株式会社 | ペプチドの遊離方法および回収方法 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| PH12014500342B1 (en) | 2011-09-16 | 2019-06-14 | Regeneron Pharma | METHODS FOR REDUCING LIPOPROTEIN (a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| EP3517550A1 (en) | 2011-11-30 | 2019-07-31 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| CN107361011B (zh) | 2012-03-16 | 2021-08-27 | 瑞泽恩制药公司 | 制备表达ph敏感性免疫球蛋白序列的非人动物的方法 |
| JP2015512245A (ja) | 2012-03-16 | 2015-04-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ｐＨ依存性の結合特徴を有する抗原結合タンパク質を産生するマウス |
| CA2865643A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
| KR101525919B1 (ko) * | 2012-05-11 | 2015-06-03 | 가톨릭대학교 산학협력단 | 자가면역 질환 예방 및 치료를 위한 ｔｎｆｒ２를 기반으로 하는 이중 항체 |
| JP6309521B2 (ja) | 2012-08-13 | 2018-04-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体 |
| KR102273985B1 (ko) | 2012-08-24 | 2021-07-06 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체 |
| RU2015119547A (ru) * | 2012-10-25 | 2016-12-20 | МЕДИММЬЮН, ЭлЭлСи | Стабильный низковязкий состав с антителом |
| US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| MX2015016887A (es) | 2013-06-07 | 2016-07-26 | Regeneron Pharma | Metodos para inhibir la aterosclerosis mediante la administracion de un inhibidor de pcsk9. |
| JP6442404B2 (ja) | 2013-06-11 | 2018-12-19 | 国立研究開発法人国立精神・神経医療研究センター | 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法 |
| ES2881306T3 (es) | 2013-09-27 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Método para la producción de heteromultímeros de polipéptidos |
| AU2014348765A1 (en) | 2013-11-12 | 2016-06-09 | Regeneron Pharmaceuticals, Inc. | Dosing regimens for use with PCSK9 inhibitors |
| US10105418B2 (en) * | 2013-12-23 | 2018-10-23 | Staley A. Brod | Oral administration of tocilizumab treatment of autoimmune disease |
| RU2732226C2 (ru) * | 2014-03-17 | 2020-09-14 | Мицубиси Танабе Фарма Корпорейшн | Конъюгаты антитело-финомер |
| KR20170029613A (ko) | 2014-07-16 | 2017-03-15 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| US11253546B2 (en) | 2014-12-15 | 2022-02-22 | The Regents Of The University Of California | Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20 |
| EP3234120A4 (en) | 2014-12-15 | 2018-05-16 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| JP6227191B1 (ja) | 2014-12-19 | 2017-11-08 | 中外製薬株式会社 | 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法 |
| TW202248212A (zh) | 2015-02-05 | 2022-12-16 | 日商中外製藥股份有限公司 | 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途 |
| ES2967627T3 (es) * | 2015-02-27 | 2024-05-03 | Chugai Pharmaceutical Co Ltd | Composición para tratar enfermedades relacionadas con IL-6 |
| ES2888801T3 (es) | 2015-05-19 | 2022-01-07 | Nat Center Neurology & Psychiatry | Método para determinar la aplicación de una terapia nueva en pacientes con esclerosis múltiple (EM) |
| EA201890519A1 (ru) | 2015-08-18 | 2018-07-31 | Ридженерон Фармасьютикалз, Инк. | Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов |
| US10266590B2 (en) | 2015-09-04 | 2019-04-23 | Momenta Pharmaceuticals, Inc. | Methods related to biologics |
| FI3368571T3 (fi) | 2015-10-30 | 2023-02-28 | Transformoivia kasvutekijä-beeta-vasteellisia polypeptidejä ja niiden käyttömenetelmiä | |
| MA43377A (fr) | 2015-12-04 | 2021-05-19 | Hutchinson Fred Cancer Res | Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| AU2016381992B2 (en) | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| BR112018069251A2 (pt) | 2016-03-22 | 2019-01-22 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | métodos de intervenção precoce para prevenir ou melhorar a toxicidade |
| WO2017201731A1 (en) * | 2016-05-27 | 2017-11-30 | Beijing Vdjbio Co., Ltd. | Antibodies, composition and kits comprising same, and methods of use thereof |
| TW202300168A (zh) | 2016-08-05 | 2023-01-01 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
| JP2019530440A (ja) * | 2016-09-02 | 2019-10-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物 |
| CA3045355A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| BR112019011702A2 (pt) | 2016-12-14 | 2019-10-22 | Progenity Inc | tratamento de uma doença do trato gastrointestinal com um inibidor de il-12/il-23 liberado usando um dispositivo ingerível |
| WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| SG11201906852XA (en) | 2017-02-01 | 2019-08-27 | Univ Yale | Treatment of diuretic resistance |
| MX2019010171A (es) | 2017-02-27 | 2019-10-15 | Juno Therapeutics Inc | Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular. |
| CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| CN114989305A (zh) * | 2017-03-31 | 2022-09-02 | 北京智仁美博生物科技有限公司 | 新型双特异性抗体及其用途 |
| US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
| WO2018223098A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
| CN111225675B (zh) | 2017-06-02 | 2024-05-03 | 朱诺治疗学股份有限公司 | 使用过继细胞疗法治疗的制品和方法 |
| MA50057A (fr) | 2017-09-01 | 2020-07-08 | Juno Therapeutics Inc | Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire |
| JP7235249B2 (ja) | 2017-10-20 | 2023-03-08 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| MA51210A (fr) | 2017-12-01 | 2020-10-07 | Juno Therapeutics Inc | Procédés de dosage et de modulation de cellules génétiquement modifiées |
| US20190241650A1 (en) | 2018-01-05 | 2019-08-08 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
| TWI822728B (zh) | 2018-01-31 | 2023-11-21 | 加藤元一 | 含有il-6抑制劑的哮喘治療劑 |
| US20210046159A1 (en) | 2018-03-09 | 2021-02-18 | Ospedale San Raffaele S.R.L. | Il-1 antagonist and toxicity induced by cell therapy |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246271A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| SG11202101674QA (en) | 2018-08-29 | 2021-03-30 | Regeneron Pharma | Methods and compositions for treating subjects having rheumatoid arthritis |
| DK3886875T3 (da) | 2018-11-30 | 2024-07-29 | Juno Therapeutics Inc | Behandlingsfremgangsmåder under anvendelse af adoptiv celleterapi |
| FI3886894T3 (fi) | 2018-11-30 | 2024-05-24 | Juno Therapeutics Inc | Menetelmiä annosteluun ja b-solumaligniteettien hoitoon adoptiivisessa soluterapiassa |
| CA3128212A1 (en) | 2019-01-31 | 2020-08-06 | Sanofi Biotechnology | Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis |
| WO2020202839A1 (ja) * | 2019-03-29 | 2020-10-08 | 中外製薬株式会社 | 抗ｉｌ－６受容体抗体を含有するｂｂｂ機能低下の抑制剤 |
| KR20220019670A (ko) | 2019-04-17 | 2022-02-17 | 고쿠리츠다이가쿠호진 히로시마다이가쿠 | Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제 |
| CN118593691A (zh) | 2019-05-03 | 2024-09-06 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
| CN114375205A (zh) | 2019-06-20 | 2022-04-19 | 武田药品工业株式会社 | 用基于病毒的基因疗法进行治疗的方法 |
| AU2020395318A1 (en) | 2019-12-06 | 2022-06-09 | Juno Therapeutics, Inc. | Methods related to toxicity and response associated with cell therapy for treating B cell malignancies |
| US20230390391A1 (en) | 2020-01-22 | 2023-12-07 | Regents Of The University Of Minnesota | Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor |
| BR112022017574A2 (pt) | 2020-03-03 | 2022-11-16 | Twentyeight Seven Inc | Compostos que têm como alvo proteínas de ligação ao rna ou proteínas modificadoras de rna |
| WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
| JP2023518814A (ja) | 2020-03-23 | 2023-05-08 | ジェネンテック， インコーポレイテッド | Ｃｏｖｉｄ－１９肺炎における、ｉｌ－６アンタゴニストに対する応答を予測するためのバイオマーカー |
| WO2021194865A1 (en) | 2020-03-23 | 2021-09-30 | Genentech, Inc. | Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist |
| EP4107186A1 (en) | 2020-03-23 | 2022-12-28 | Genentech, Inc. | Tocilizumab and remdesivir combination therapy for covid-19 pneumonia |
| WO2021202919A1 (en) * | 2020-04-01 | 2021-10-07 | The University Of Chicago | Tocilizumab for the treatment of viral infections |
| CN116685351A (zh) | 2020-09-17 | 2023-09-01 | 基因泰克公司 | Empacta的结果：一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究 |
| WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| TW202241469A (zh) | 2021-02-20 | 2022-11-01 | 美商凱特製藥公司 | 免疫療法 |
| IL305793A (en) | 2021-03-12 | 2023-11-01 | Hoffmann La Roche | A pharmaceutical preparation for the treatment or prevention of myasthenia gravis |
| CA3217354A1 (en) | 2021-05-14 | 2022-11-17 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| WO2023119638A1 (en) * | 2021-12-24 | 2023-06-29 | Chugai Seiyaku Kabushiki Kaisha | Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab |
| WO2023095854A1 (en) * | 2021-11-26 | 2023-06-01 | Chugai Seiyaku Kabushiki Kaisha | Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab |
| WO2023095305A1 (en) * | 2021-11-26 | 2023-06-01 | Chugai Seiyaku Kabushiki Kaisha | Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab |
| TW202337495A (zh) | 2022-01-19 | 2023-10-01 | 日商中外製藥股份有限公司 | 用satralizumab治療自體免疫腦炎 |
| US20230296610A1 (en) | 2022-02-15 | 2023-09-21 | Kite Pharma, Inc. | Predicting adverse events from immunotherapy |
| CN114525235B (zh) * | 2022-02-25 | 2023-07-14 | 郑州大学 | 一种提高人表皮生长因子分泌生产效率的方法 |
| WO2024107752A2 (en) | 2022-11-15 | 2024-05-23 | Onestone Therapeutics Llc | Compositions and methods for immunomodulatory bifunctional fusion molecules |
| US20240200085A1 (en) | 2022-12-15 | 2024-06-20 | Aarhus Universitet | Synthetic activation of multimeric transmembrane receptors |
| WO2024196689A1 (en) | 2023-03-17 | 2024-09-26 | Kite Pharma, Inc. | Impact of tumor microenvironment on efficacy of immunotherapy |
| WO2024225417A1 (en) * | 2023-04-28 | 2024-10-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of thyroid eye disease with satralizumab |
Family Cites Families (212)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5144499B1 (es) | 1970-08-29 | 1976-11-29 | ||
| JPS5334319B2 (es) | 1971-12-28 | 1978-09-20 | ||
| JPS5717624B2 (es) | 1974-04-17 | 1982-04-12 | ||
| JPS5484060A (en) | 1977-12-12 | 1979-07-04 | Kyushu Sekisui Kogyo | Treatment of raw *wakame* by using chlorella extract |
| US4324710A (en) | 1980-10-02 | 1982-04-13 | The Firestone Tire & Rubber Company | Naturally occurring thermoplastic resins as a substitute for various petroleum-derived materials in rubber stocks |
| US4769320A (en) | 1982-07-27 | 1988-09-06 | New England Medical Center Hospitals, Inc. | Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations |
| US4689299A (en) | 1982-09-30 | 1987-08-25 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
| JPH06104071B2 (ja) | 1986-08-24 | 1994-12-21 | 財団法人化学及血清療法研究所 | 第▲ｉｘ▼因子コンホメ−シヨン特異性モノクロ−ナル抗体 |
| US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5670373A (en) * | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| US5322678A (en) * | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| AR242986A1 (es) | 1988-09-28 | 1993-06-30 | Lilly Co Eli | Un metodo de reduccion de la heterogeneidad de anticuerpos secretados por celulas productoras de anticuerpo. |
| US5126250A (en) * | 1988-09-28 | 1992-06-30 | Eli Lilly And Company | Method for the reduction of heterogeneity of monoclonal antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5202253A (en) | 1988-12-30 | 1993-04-13 | Oklahoma Medical Research Foundation | Monoclonal antibody specific for protein C and antibody purification method |
| JPH0636741B2 (ja) | 1989-11-08 | 1994-05-18 | 帝人株式会社 | ヒト・プロテインｃの分離方法 |
| WO1991012023A2 (en) | 1990-02-16 | 1991-08-22 | Boston Biomedical Research Institute | Hybrid reagents capable of selectively releasing molecules into cells |
| US5795965A (en) * | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE322547T1 (de) | 1993-06-10 | 2006-04-15 | Genetic Therapy Inc | Adenovirale vektoren für die behandlung der hämophilie |
| IL107742A0 (en) | 1993-11-24 | 1994-02-27 | Yeda Res & Dev | Chemically-modified binding proteins |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5945311A (en) * | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
| DE122009000068I2 (de) | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| US8017121B2 (en) * | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| US6309636B1 (en) | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| CN101601861A (zh) | 1994-10-07 | 2009-12-16 | 中外制药株式会社 | 以il-6拮抗剂作为有效成分治疗慢性类风湿性关节炎 |
| WO1996012503A1 (fr) | 1994-10-21 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Remede contre des maladies provoquees par la production d'il-6 |
| US6485943B2 (en) | 1995-01-17 | 2002-11-26 | The University Of Chicago | Method for altering antibody light chain interactions |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5830478A (en) | 1995-06-07 | 1998-11-03 | Boston Biomedical Research Institute | Method for delivering functional domains of diphtheria toxin to a cellular target |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| TW518219B (en) | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| IL127872A0 (en) | 1996-07-19 | 1999-10-28 | Amgen Inc | Analogs of cationic proteins |
| US5990286A (en) | 1996-12-18 | 1999-11-23 | Techniclone, Inc. | Antibodies with reduced net positive charge |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| CA2284271C (en) | 1997-03-21 | 2012-05-08 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient |
| US20070059302A1 (en) * | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020187150A1 (en) * | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| CA2296322A1 (en) | 1997-08-15 | 1999-02-25 | Chugai Seiyaku Kabushiki Kaisha | Preventives and/or remedies for systemic lupus erythematosus containing anti-il-6 receptor antibody as the active ingredient |
| CN1277632A (zh) * | 1997-10-03 | 2000-12-20 | 中外制药株式会社 | 天然人源化抗体 |
| PL199659B1 (pl) | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
| KR100407811B1 (ko) * | 1998-03-17 | 2003-12-01 | 츄가이 세이야꾸 가부시키가이샤 | 인터루킨-6 안타고니스트를 유효성분으로서 함유하는 염증성 장질환의 예방 또는 치료제 |
| IL138801A0 (en) | 1998-04-03 | 2001-10-31 | Chugai Pharmaceutical Co Ltd | Humanized antibody against human tissue factor and process for the preparation thereof |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| AU770555B2 (en) * | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6475718B2 (en) | 1998-09-08 | 2002-11-05 | Schering Aktiengesellschaft | Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| ATE477273T1 (de) * | 1998-12-01 | 2010-08-15 | Facet Biotech Corp | Humanisierte antikoerper gegen gamma-interferon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| SE9903895D0 (sv) | 1999-10-28 | 1999-10-28 | Active Biotech Ab | Novel compounds |
| HUP0301835A2 (hu) | 2000-05-03 | 2003-09-29 | Mbt Munich Biotechnology Ag | Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva |
| AU6842701A (en) | 2000-06-16 | 2002-01-14 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
| PT1334731E (pt) | 2000-10-25 | 2008-03-11 | Chugai Pharmaceutical Co Ltd | Agentes preventivos ou medicamentos para a psoríase que contêm um antagonista da il-6 como ingrediente activo |
| JP4889187B2 (ja) * | 2000-10-27 | 2012-03-07 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤 |
| JP3899804B2 (ja) * | 2000-11-27 | 2007-03-28 | 富士ゼロックス株式会社 | 画像処理装置、画像処理方法および画像処理プログラムを記録した記憶媒体 |
| DE60143544D1 (de) | 2000-12-12 | 2011-01-05 | Medimmune Llc | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
| CA2440221C (en) | 2001-03-07 | 2013-02-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Expression technology for proteins containing a hybrid isotype antibody moiety |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| US7358054B2 (en) * | 2001-04-13 | 2008-04-15 | Biogen Idec Ma Inc. | Antibodies to VLA-1 |
| US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| EP1780273B1 (en) * | 2001-06-22 | 2010-10-06 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitors containing anti-glypican 3 antibody |
| US20040161741A1 (en) | 2001-06-30 | 2004-08-19 | Elazar Rabani | Novel compositions and processes for analyte detection, quantification and amplification |
| US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
| BRPI0214168B8 (pt) * | 2001-11-14 | 2021-05-25 | Centocor Inc | anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos |
| KR20040082421A (ko) | 2002-02-11 | 2004-09-24 | 제넨테크, 인크. | 빠른 항원 결합 속도를 갖는 항체 변이체 |
| DE60334678D1 (de) | 2002-02-14 | 2010-12-09 | Chugai Pharmaceutical Co Ltd | Antikörper enthaltende pharmazeutische lösungen |
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| US20050130224A1 (en) * | 2002-05-31 | 2005-06-16 | Celestar Lexico- Sciences, Inc. | Interaction predicting device |
| AU2003248652A1 (en) | 2002-06-12 | 2003-12-31 | Genencor International, Inc. | Methods for improving a binding characteristic of a molecule |
| WO2003105757A2 (en) | 2002-06-12 | 2003-12-24 | Genencor International, Inc. | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
| JP3856734B2 (ja) | 2002-06-28 | 2006-12-13 | 株式会社日立製作所 | 多発性硬化症に対するインターフェロン・ベータ薬物治療の有効性予測方法 |
| AU2003264009A1 (en) | 2002-08-15 | 2004-03-03 | Epitomics, Inc. | Humanized rabbit antibodies |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2502904C (en) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2003299898B2 (en) | 2002-12-24 | 2010-12-16 | Rinat Neuroscience Corp. | Anti-NGF antibodies and methods using same |
| EP1608684A2 (en) | 2003-02-07 | 2005-12-28 | Protein Design Labs, Inc. | Amphiregulin antibodies and their use to treat cancer and psoriasis |
| AU2004215653B2 (en) | 2003-02-28 | 2011-03-17 | Lonza Biologics Plc. | Antibody purification by protein A and ion exchange chromatography |
| CN1798767B (zh) | 2003-04-10 | 2011-02-16 | 晶面生物技术公司 | 通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期 |
| GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| WO2004109443A2 (en) * | 2003-06-02 | 2004-12-16 | Liquid Machines, Inc. | Managing data objects in dynamic, distributed and collaborative contexts |
| PL1631313T3 (pl) | 2003-06-05 | 2015-08-31 | Genentech Inc | Terapia skojarzona zaburzeń z komórek B |
| EP1636264A2 (en) | 2003-06-24 | 2006-03-22 | MERCK PATENT GmbH | Tumour necrosis factor receptor molecules with reduced immunogenicity |
| US20050033029A1 (en) | 2003-06-30 | 2005-02-10 | Jin Lu | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
| EP1663306A2 (en) | 2003-09-05 | 2006-06-07 | Genentech, Inc. | Antibodies with altered effector functions |
| JP2005101105A (ja) | 2003-09-22 | 2005-04-14 | Canon Inc | 位置決め装置、露光装置、デバイス製造方法 |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| EP1693448A4 (en) | 2003-10-14 | 2008-03-05 | Chugai Pharmaceutical Co Ltd | DOUBLE SPECIFICITY ANTIBODY FOR FUNCTIONAL PROTEIN SUBSTITUTION |
| AR046290A1 (es) | 2003-10-17 | 2005-11-30 | Chugai Pharmaceutical Co Ltd | Agente terapeutico para el mesotelioma |
| WO2005049649A1 (en) | 2003-11-05 | 2005-06-02 | Ares Trading S.A. | Process for the purification of il-18 binding protein |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| EP1701979A2 (en) | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Optimized antibodies that target the epidermal growth factor receptor |
| PL2418220T3 (pl) | 2003-12-10 | 2017-12-29 | E. R. Squibb & Sons, L.L.C. | Przeciwciała przeciwko interferonowi alfa i ich zastosowania |
| AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
| DK2177537T3 (da) | 2004-01-09 | 2011-12-12 | Pfizer | Antistoffer til MAdCAM |
| BRPI0506679A (pt) | 2004-02-11 | 2007-05-15 | Warner Lambert Co | métodos de tratar osteoartrite com antagonistas de il-6 |
| EP3736295A1 (en) | 2004-03-24 | 2020-11-11 | Chugai Seiyaku Kabushiki Kaisha | Subtypes of humanized antibody against interleukin-6 receptor |
| AR048335A1 (es) | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo |
| KR20070035482A (ko) * | 2004-03-24 | 2007-03-30 | 추가이 세이야쿠 가부시키가이샤 | 인터로킨-6 안타고니스트를 활성성분으로 함유하는내이장해 치료제 |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
| WO2005112564A2 (en) | 2004-04-15 | 2005-12-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Germline and sequence variants of humanized antibodies and methods of making and using them |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| WO2006009901A2 (en) | 2004-06-18 | 2006-01-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
| JP2008504289A (ja) | 2004-06-25 | 2008-02-14 | メディミューン，インコーポレーテッド | 部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加 |
| ES2372503T3 (es) | 2004-07-06 | 2012-01-20 | Bioren, Inc. | Mutagénesis revisada para desarrollar polipéptidos alterados con propiedades potenciadas. |
| PL2471813T3 (pl) | 2004-07-15 | 2015-09-30 | Xencor Inc | Zoptymalizowane warianty Fc |
| US20080233131A1 (en) | 2004-09-14 | 2008-09-25 | Richard John Stebbings | Vaccine |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| US7928205B2 (en) | 2004-10-22 | 2011-04-19 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| US7632497B2 (en) * | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20090061485A1 (en) | 2004-12-22 | 2009-03-05 | Chugai Seiyaku Kabushiki Kaisha | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited |
| RU2440582C2 (ru) | 2004-12-23 | 2012-01-20 | Ново Нордиск А/С | Аффинные лиганды, связывающие антитела |
| US20090087478A1 (en) | 2004-12-27 | 2009-04-02 | Progenics Pharmaceuticals (Nevada), Inc. | Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them |
| EP1831258B2 (en) | 2004-12-28 | 2023-06-07 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
| JP4986633B2 (ja) | 2005-01-12 | 2012-07-25 | 協和発酵キリン株式会社 | 安定化されたヒトＩｇＧ２およびＩｇＧ３抗体 |
| WO2006076594A2 (en) * | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
| TW200714313A (en) * | 2005-04-08 | 2007-04-16 | Chugai Pharmaceutical Co Ltd | Antibodies that substitute for coagulation factor VIII |
| PE20061324A1 (es) | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
| AU2006244445B2 (en) | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
| AU2006279945B2 (en) | 2005-08-10 | 2012-04-12 | Macrogenics, Inc. | Identification and engineering of antibodies with variant FC regions and methods of using same |
| BRPI0614893A2 (pt) | 2005-08-19 | 2010-03-30 | Wyeth Corp | anticorpo isolado capaz de ligar gdf-8, polinucleotìdeo isolado, célula hospedeira, vetor, método para produzir um anticorpo, in vitro para diagnosticar ou detectar se um paciente está sofrendo de um distúrbio associado com gdf-8 para monitorar a severidade de um distúrbio associado com gdf-8 e para prognosticar a possibilidade de que um paciente irá desenvolver um distúrbio associado com gdf-8, anticorpo isolado e purificado, composição farmacêutica para tratar, melhorar e/ ou prevenir um distúrbio associado com gdf-8, e, usos de uma quantidade eficaz do anticorpo e do polinucleotìdeo |
| CA2622772A1 (en) | 2005-09-29 | 2007-04-12 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| AR061400A1 (es) | 2005-10-14 | 2008-08-27 | Chugai Kabushiki Kaisha | Agentes para suprimir el dano a los islotes transplantados despues del transplante de islotes |
| RU2450830C2 (ru) | 2005-10-21 | 2012-05-20 | Чугаи Сейяку Кабусики Кайся | Средства для лечения кардиопатии |
| EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| WO2007060411A1 (en) | 2005-11-24 | 2007-05-31 | Ucb Pharma S.A. | Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r |
| AR057941A1 (es) | 2005-11-25 | 2007-12-26 | Univ Keio | Agentes terapeuticos para el cancer de prostata |
| US9084777B2 (en) * | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
| EP3219328B1 (en) | 2005-12-29 | 2020-06-17 | Janssen Biotech, Inc. | Human anti-il-23 antibodies, compositions, method and uses |
| CA2637917C (en) | 2006-01-27 | 2015-11-24 | Keio University | Therapeutic agents for diseases involving choroidal neovascularization |
| CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| EP2006380A4 (en) | 2006-03-23 | 2010-08-11 | Kyowa Hakko Kirin Co Ltd | AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR |
| EP4218801A3 (en) * | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| CN101479381B (zh) * | 2006-03-31 | 2015-04-29 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| WO2007116962A1 (ja) | 2006-04-07 | 2007-10-18 | Osaka University | 筋再生促進剤 |
| EP2027157B1 (en) * | 2006-05-25 | 2014-08-06 | Glaxo Group Limited | Modified humanised anti-interleukin-18 antibodies |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| NZ573557A (en) * | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US9028821B2 (en) * | 2006-06-08 | 2015-05-12 | Chugai Seiyaku Kabushiki Kaisha | Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist |
| CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| CA2665287C (en) | 2006-10-06 | 2022-08-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Prevention of tissue ischemia, related methods and compositions |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| KR101508019B1 (ko) | 2007-01-23 | 2015-04-06 | 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 | 만성 거부반응 억제제 |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| WO2008145141A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
| CN101679009B (zh) * | 2007-06-18 | 2014-04-16 | 因温特奥股份公司 | 用于监视制动装置的装置和方法 |
| CA2691974C (en) | 2007-06-29 | 2016-08-30 | Quest Diagnostics Investments Incorporated | Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry |
| WO2009010539A2 (en) | 2007-07-19 | 2009-01-22 | Ablynx. N.V. | Receptor for interleukin-6 (il-6) from macaca fascicularis |
| WO2009014263A1 (ja) | 2007-07-26 | 2009-01-29 | Osaka University | インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤 |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| AU2008298904B2 (en) | 2007-09-14 | 2014-10-16 | Amgen Inc. | Homogeneous antibody populations |
| EP2202245B1 (en) * | 2007-09-26 | 2016-08-24 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| CN101874041B (zh) * | 2007-09-26 | 2013-06-19 | 中外制药株式会社 | 抗体恒定区修饰体 |
| WO2009041734A1 (ja) | 2007-09-26 | 2009-04-02 | Kyowa Hakko Kirin Co., Ltd. | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
| CN101939425B (zh) | 2007-09-26 | 2014-05-14 | 中外制药株式会社 | 抗il-6受体抗体 |
| MY148637A (en) | 2007-09-28 | 2013-05-15 | Chugai Pharmaceutical Co Ltd | Anti-glypican-3 antibody having improved kinetics in plasma |
| EP2196220B1 (en) | 2007-10-02 | 2014-12-03 | Chugai Seiyaku Kabushiki Kaisha | Inhibting anti-IL-6 receptor antibody for treating graft-versus-host disease |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US20110129459A1 (en) | 2007-12-05 | 2011-06-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-nr10 antibody and use thereof |
| EP2261254A3 (en) | 2007-12-21 | 2011-04-13 | Amgen, Inc | Anti-amyloid antibodies and uses thereof |
| SG188129A1 (en) | 2008-02-08 | 2013-03-28 | Medimmune Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| TW201447062A (zh) * | 2008-04-11 | 2014-12-16 | Chugai Pharmaceutical Co Ltd | 重複結合複數個抗原的抗原結合分子 |
| US9315577B2 (en) | 2008-05-01 | 2016-04-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| CN104906581A (zh) | 2008-06-05 | 2015-09-16 | 国立研究开发法人国立癌症研究中心 | 神经浸润抑制剂 |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| PL2352521T3 (pl) | 2008-10-14 | 2021-03-08 | Genentech, Inc. | Warianty immunoglobuliny i ich zastosowania |
| CN103861106B (zh) | 2008-11-25 | 2017-03-22 | 奥尔德生物制药公司 | 增加白蛋白和/或减少crp的il‑6拮抗剂 |
| EP2400981A4 (en) | 2009-02-26 | 2013-02-27 | Lpath Inc | DESGIN FOR HUMANIZED THROMBOZYTE ACTIVATION FACTOR ANTIBODIES BY ANTI-LIPID ANTIBODY TEMPLATES |
| EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| EP2409990A4 (en) | 2009-03-19 | 2013-01-23 | Chugai Pharmaceutical Co Ltd | VARIANT OF A CONSTANT ANTIBODY REGION |
| SG10201703707YA (en) | 2009-03-19 | 2017-06-29 | Chugai Pharmaceutical Co Ltd | Pharmaceutical formulation containing improved antibody molecules |
| TWI457134B (zh) | 2009-03-19 | 2014-10-21 | Chugai Pharmaceutical Co Ltd | Rheumatoid arthritis treatment |
| SG10201404340TA (en) | 2009-07-31 | 2014-10-30 | Shin Maeda | Cancer metastasis inhibitor |
| US10150808B2 (en) * | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| JP6101489B2 (ja) | 2010-01-28 | 2017-03-22 | アブ バイオサイエンシズ インコーポレイテッド | 親和性が低下した抗体およびそれを作製する方法 |
| PL3053932T3 (pl) | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
| AU2011225716A1 (en) | 2010-03-11 | 2012-09-27 | Pfizer Inc. | Antibodies with pH dependent antigen binding |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| EP2578233B1 (en) | 2010-05-28 | 2017-04-26 | National Cancer Center | Therapeutic agent for pancreatic cancer |
| DK2578231T3 (da) | 2010-05-28 | 2022-12-12 | Chugai Pharmaceutical Co Ltd | Antitumor-t-celle-reaktionsforstærker |
| JP2013541594A (ja) | 2010-11-08 | 2013-11-14 | ジェネンテック， インコーポレイテッド | 皮下投与される抗ｉｌ−６受容体抗体 |
| WO2012063875A1 (ja) | 2010-11-11 | 2012-05-18 | シスメックス株式会社 | ヒト濾胞ヘルパーt細胞検出用マーカーおよびヒト濾胞ヘルパーt細胞の検出方法 |
| KR102385507B1 (ko) | 2010-11-30 | 2022-04-12 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| US20140093496A1 (en) | 2011-02-25 | 2014-04-03 | Chugai Seiyaku Kabushiki Kaisha | Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY |
| JP6271254B2 (ja) | 2011-02-28 | 2018-01-31 | ジェネンテック， インコーポレイテッド | Ｂ細胞アンタゴニストに対する生物学的マーカー及び応答を予測するための方法 |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| EP2765192A4 (en) | 2011-10-05 | 2015-04-15 | Chugai Pharmaceutical Co Ltd | ANTIGEN BINDING MOLECULE FOR PROMOTING THE PLASMA CLAIR OF AN ANTIGEN COMPRISING A SACCHARIDIC CHAIN TYPE RECEPTOR BINDING DOMAIN |
| EP3517550A1 (en) | 2011-11-30 | 2019-07-31 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
| CN104244980B (zh) | 2012-02-24 | 2017-11-10 | 中外制药株式会社 | 经由FcγIIB促进抗原消除的抗原结合分子 |
| WO2013180201A1 (ja) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 会合化した抗原を消失させる抗原結合分子 |
| JP6309521B2 (ja) | 2012-08-13 | 2018-04-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体 |
| US20160032014A1 (en) | 2013-03-15 | 2016-02-04 | Amgen Inc. | Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 |
| US9321686B2 (en) | 2013-03-15 | 2016-04-26 | Forta Corporation | Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete |
| US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| JP6442404B2 (ja) | 2013-06-11 | 2018-12-19 | 国立研究開発法人国立精神・神経医療研究センター | 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法 |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| ES2967627T3 (es) | 2015-02-27 | 2024-05-03 | Chugai Pharmaceutical Co Ltd | Composición para tratar enfermedades relacionadas con IL-6 |
| ES2888801T3 (es) | 2015-05-19 | 2022-01-07 | Nat Center Neurology & Psychiatry | Método para determinar la aplicación de una terapia nueva en pacientes con esclerosis múltiple (EM) |
-
2009
- 2009-09-16 TW TW098131191A patent/TWI440469B/zh active
- 2009-09-25 NZ NZ592214A patent/NZ592214A/xx not_active IP Right Cessation
- 2009-09-25 DK DK09816184.7T patent/DK2330193T3/en active
- 2009-09-25 KR KR1020107007620A patent/KR101044180B1/ko active IP Right Grant
- 2009-09-25 CA CA2699834A patent/CA2699834C/en active Active
- 2009-09-25 AU AU2009290162A patent/AU2009290162B2/en active Active
- 2009-09-25 HU HUE09816184A patent/HUE027533T2/en unknown
- 2009-09-25 RU RU2010111890A patent/RU2430111C3/ru active Protection Beyond IP Right Term
- 2009-09-25 JP JP2009552949A patent/JP4550938B2/ja active Active
- 2009-09-25 CN CN2009801007096A patent/CN101849006B/zh active Active
- 2009-09-25 MX MX2010003256A patent/MX2010003256A/es active IP Right Grant
- 2009-09-25 CA CA2763039A patent/CA2763039C/en not_active Expired - Fee Related
- 2009-09-25 WO PCT/JP2009/066590 patent/WO2010035769A1/ja active Application Filing
- 2009-09-25 EP EP09816184.7A patent/EP2330193B1/en active Active
- 2009-09-25 ES ES09816184.7T patent/ES2546800T3/es active Active
- 2009-09-25 MY MYPI2010001102A patent/MY153908A/en unknown
- 2009-09-25 PL PL09816184T patent/PL2330193T3/pl unknown
- 2009-09-25 CN CN201310127358.6A patent/CN103254310B/zh not_active Expired - Fee Related
- 2009-09-25 PT PT98161847T patent/PT2330193E/pt unknown
- 2009-09-25 US US12/680,087 patent/US8562991B2/en active Active
- 2009-09-25 BR BRPI0905076A patent/BRPI0905076B8/pt active IP Right Grant
- 2009-09-25 AR ARP090103711A patent/AR073404A1/es active IP Right Grant
- 2009-09-25 PE PE2011000788A patent/PE20120079A1/es not_active Application Discontinuation
- 2009-09-25 SI SI200931268T patent/SI2330193T1/sl unknown
- 2009-09-25 KR KR1020107007644A patent/KR101690334B1/ko active IP Right Grant
-
2010
- 2010-01-26 JP JP2010013833A patent/JP5661291B2/ja active Active
-
2011
- 2011-02-01 HK HK11101085.1A patent/HK1147107A1/xx unknown
- 2011-03-22 IL IL211850A patent/IL211850A0/en unknown
- 2011-03-24 CL CL2011000632A patent/CL2011000632A1/es unknown
- 2011-04-12 MA MA33765A patent/MA32707B1/fr unknown
- 2011-04-12 CO CO11045364A patent/CO6362048A2/es active IP Right Grant
- 2011-04-15 CR CR20110204A patent/CR20110204A/es unknown
- 2011-04-19 ZA ZA2011/03027A patent/ZA201103027B/en unknown
- 2011-04-25 EC EC2011011003A patent/ECSP11011003A/es unknown
-
2012
- 2012-06-15 US US13/524,528 patent/US20120253016A1/en not_active Abandoned
-
2013
- 2013-11-26 HK HK13113190.6A patent/HK1185887A1/xx not_active IP Right Cessation
-
2014
- 2014-10-22 US US14/520,423 patent/US10662245B2/en active Active
-
2015
- 2015-08-11 HR HRP20150857TT patent/HRP20150857T1/hr unknown
-
2020
- 2020-04-02 US US16/838,415 patent/US20200231688A1/en not_active Abandoned
-
2021
- 2021-10-25 US US17/509,128 patent/US20220041741A1/en not_active Abandoned
- 2021-11-10 FR FR21C1054C patent/FR21C1054I2/fr active Active
- 2021-11-11 NO NO2021048C patent/NO2021048I1/no unknown
- 2021-11-12 HU HUS2100050C patent/HUS2100050I1/hu unknown
- 2021-11-17 LT LTPA2021013C patent/LTC2330193I2/lt unknown
- 2021-12-08 NL NL301152C patent/NL301152I2/nl unknown
- 2021-12-13 FI FIC20210049C patent/FIC20210049I1/fi unknown
-
2022
- 2022-06-01 US US17/829,641 patent/US20220306755A1/en not_active Abandoned
- 2022-09-08 AR ARP220102433A patent/AR127010A2/es unknown
-
2023
- 2023-01-12 US US18/096,066 patent/US20230159648A1/en not_active Abandoned
- 2023-09-11 US US18/464,407 patent/US20240010738A1/en not_active Abandoned
-
2024
- 2024-05-01 US US18/651,896 patent/US20240301075A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6362048A2 (es) | Moleculas de anticuerpo mejoradas | |
| CO2018010919A2 (es) | Moleculas de unión b7-h3 novedosas, conjugados anticuerpo - fármaco de los mismos y métodos de uso de los mismos | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| EA201291355A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ОБОГАЩЕННОЙ IgG-КОМПОЗИЦИИ ИЗ ПЛАЗМЫ | |
| AR117911A2 (es) | Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| RU2016111131A (ru) | Способы конъюгации сайт-специфических антител и композиции | |
| SG10201900451SA (en) | Pharmaceutical formulation containing improved antibody molecules | |
| CR20160319A (es) | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este | |
| TN2014000206A1 (en) | Antibody molecules having specificity for human ox40 | |
| ECSP15017314A (es) | Formulacion de anticuerpos | |
| CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
| CR20140267A (es) | Metodos para tratar transtornos relacionados con mutante viii de eliminacion de factor de crecimiento epidérmico | |
| RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
| JP2017508466A5 (es) | ||
| NZ607710A (en) | 4-1bb binding molecules | |
| JP2016513710A5 (es) | ||
| AR066660A1 (es) | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento | |
| CY1120213T1 (el) | Antαγωνιστες φθοριωμενης ιντεγκρινης | |
| RU2015118180A (ru) | Антитела к бета-амилоиду | |
| MX2021005823A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno y uso farmaceutico del mismo. | |
| RU2014140744A (ru) | Композиции, содержащие секреторноподобные иммуноглобулины | |
| RU2014140116A (ru) | Антитела против pdgf-c | |
| EP2358395A4 (en) | METHOD AND FORMULATION FOR REDUCING THE AGGREGATION OF A MACROMOLECULUM UNDER PHYSIOLOGICAL CONDITIONS | |
| AR096601A1 (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso | |
| CY1121249T1 (el) | Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |